8-K – 2025-10-17 – d32252d8k.htm

8-K

false 0001628171 0001628171 2025-10-16 2025-10-16 0001628171 rvmdw:CommonStock0.0001ParValuePerShareMember 2025-10-16 2025-10-16 0001628171 rvmdw:WarrantsToPurchase0.1112SharesOfCommonStockExpiring2026Member 2025-10-16 2025-10-16
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 8-K
 
 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 16, 2025
 
 

REVOLUTION MEDICINES, INC.
(Exact name of registrant as specified in its charter)
 
 

 

Delaware
 
001-39219
 
47-2029180

(State or other jurisdiction
of incorporation)

 
(Commission
File Number)

 
(IRS Employer
Identification No.)

 

700 Saginaw Drive
 

Redwood City , California
 
94063

(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (650) 481-6801
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 

Title of each class

 
Trading
Symbol

 
Name of each exchange
on which registered

Common Stock, $0.0001 par value per share
 
RVMD
 
The Nasdaq Stock Market LLC

Warrants to purchase 0.1112 shares of common stock expiring 2026
 
RVMDW
 
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 

Item 8.01
Other Events.

On October 16, 2025, Revolution Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has granted the Company a non-transferrable voucher for daraxonrasib, the Company’s RAS(ON) multi-selective inhibitor, under the Commissioner’s National Priority Voucher pilot program.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 

 
REVOLUTION MEDICINES, INC.

Date: October 16, 2025
 

 
By:
 
/s/ Mark A. Goldsmith

 

 

 
Mark A. Goldsmith, M.D., Ph.D.

 

 

 
President and Chief Executive Officer